A new Phase 2 clinical study is now enrolling adults with moderate to severe asthma to evaluate the safety and efficacy of ...

Monthly injection with tezepelumab helped 90% of patients with severe asthma reduce intake of daily steroid tablets. The corresponding study was published in The Lancet Respiratory Medicine. “In this ...

A monthly injection has helped 90% of severe asthma patients reduce daily steroid tablets, which are associated with long-term side effects. More than half of the participants who had received the ...

Please provide your email address to receive an email when new articles are posted on . Epinephrine may be given via intramuscular and subcutaneous injections. Intramuscular and subcutaneous ...

A monthly injection for managing severe asthma could help patients safely reduce or even discontinue daily steroid medications, according to a new phase 3b clinical trial published in The Lancet ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo ...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair ...